Please assess the completion status of the following clinical trial:

Trial Title: Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic Parkinson'd Disease in accordance with the United Kingdom (UK) Brain Bank Criteria~* Hoehn \& Yahr scores of II-IV~* subjective report of experiencing at least 1hr/day (two, half-hour periods) of ON time with troublesome Levodopa-Induced Dyskinesia (LID)~* ambulation with or without aids (e.g., walker or cane)~* ≥30 days of a stable regimen of anti-Parkinson's medications that includes a levodopa dose administered ≥3 times daily~* a stable dose of levodopa throughout the study~* no amantadine for a minimum of 30 days prior to enrollment in the study~Exclusion Criteria:~* neurological or musculoskeletal disorders~* orthostatic hypotension at screening (defined as a drop of ≥20mm mercury (HG) systolic and ≥10mm HG diastolic at 2 or 5 minutes of quiet standing after 5 minutes of supine rest)~* a major psychotic disorder~* contraindication to GOCOVRI™ at time of screening, especially renal impairment estimated by glomerular filtration rate (eGFR) \< 50 ml/min/1.73 m2) as impaired renal function can increase the chances of adverse reactions to the study drug~* mild to severe cognitive impairment as measured by Montreal Cognitive Assessment (MoCA) score ≤ 23~* concurrent use of immediate release amantadine~* are pregnant or plan to become pregnant~* an implanted deep brain stimulator

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- GOCOVRI Treatment (Type: EXPERIMENTAL): All participants will have gait, balance, dyskinesia assessed before and after receiving GOCOVRI (274 mg/day).

Based on this trial design, predict the completion outcome and termination type (if applicable).